At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SAVA Cassava Sciences Inc
Market Closed 12-20 16:00:00 EST
2.35
+0.06
+2.62%
盘后2.35
+0.000.00%
19:57 EST
High2.41
Low2.23
Vol3.20M
Open2.24
D1 Closing2.29
Amplitude7.86%
Mkt Cap113.06M
Tradable Cap101.69M
Total Shares48.11M
T/O7.46M
T/O Rate7.40%
Tradable Shares43.27M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Lost Money on Cassava Sciences, Inc.(SAVA)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky LLP
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.